Abstract
The medical treatment of established spasticity is principally of symptomatic nature, since spasticity is generally a consequence of irreversible central nervous system damage. This damage is not amenable to causative treatment. As spasticity presents with polymorphic clinical pictures resulting in various types and degrees of discomfort and dysfunction, the aim of the symptomatic treatment also varies. In general, it includes relief of subjective discomfort, facilitation of patient care, improvement of functional capacity, and protection of the long-term consequences of unevenly distributed excessive muscle tone. Theoretically, the main aim of an antispastic agent is to reduce increased muscle tone, given the definition of spasticity in strictly physiologic terms as a “velocity-dependent increase in tonic stretch reflexes (muscle tone)” (Lance 1980). However, spasticity is associated with other symptoms including brisk tendon reflexes, clonus, flexor, extensor, or adductor spasms which can be painful, loss of dexterity, and paresis, all of which constitute the upper motor neuron or spastic syndrome. Indeed, spasticity is sometimes used as a synonym for the upper motor neuron syndrome (Young and Delwaide 1981). The other positive signs of this syndrome, such as clonus and release phenomena (flexor reflex, spasms), are also amenable to medical treatment, whereas negative signs such as loss of dexterity and paresis are not.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Berger FM, Bradley W (1946) The pharmacological properties of a β-dihyroxy-γ (2-methyl-phenoxy)-propone (Myanesine). Br J Pharmacol 1:265–272
Bittencourt PRM (1988) Oxcarbazepine and spasticity. Arq Neuropsiquiatr 46:382–384
Bittencourt PRM, Silvado CES (1985) Oxcarbazepine, GP 47779, and spasticity. Lancet 21:676
Chantraine A, Van Ouwenaller C (1988) Modified-release tizanidine in the treatment of spasticity. J Int Med Res 16:459–465
Coward DM (1981) Selective muscle relaxant properties of tizanidine and an examination of its mode of action. Triangle 20:151–158
Curtis DR, Leah JD, Peet MJ (1983) Spinal interneurone depression by DS 103–282. Br J Pharmacol 79:9–11
Das TK, Park DM, Collings AD (1989) Botulinum toxin in the treatment of spasticity. J Neurol Neurosurg Psychiatry 52:1209
Davies J (1982) Selective depression of synaptic transmission of spinal neurons in the cat by a new centrally acting muscle relaxant, DS 103–282. Br J Pharmacol 76:473–481
Davies, J, Johnston SE, Lovering R (1983) Inhibition by DS 103–282 of D-(3H) aspartate release from spinal cord slices. Br J Pharmacol 78:2P
Davies J, Johnston SE, Hill DR, Quinlan JE (1984) Tizanidine (DS 103–282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at a2-adrenoceptors. Neurosci Lett 48:197–202
Emre M (1989) Review of clinical trials with tizanidine (Sirdalud) in spasticity. In: Emre M, Benecke R (eds) Spasticity: the current status of research and treatment. Parthenon, Cornforth, pp 153–184
Hattab JR (1980) Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Year Book Medical Publishers, Chicago, pp 71–85
Jones RF, Anthony M, Torda TA, Poulos C (1988) Epidural baclofen for intractable spasticity. Lancet 1:527
Lance JW (1980) Symposium synopsis. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Year Book Medical Publishers, Chicago, pp 485–494
Lazorthes J (1988) Chronic intrathecal administration of baclofen in treatment of severe spasticity. In: Müller H, Zierski J, Penn RD (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York, pp 215–222
Lee KC, Patterson V (1990) A double-blind study of L-threonine in patients with spasticity. J Neurol Neurosurg Psychiatry 53:181
Lodge D (ed) (1988) Excitatory amino acids in health and disease. Wiley, Chichester
Mazzocchio R, Schieppati M, Scarpini C, Rossi A (1990) Enhancement of recurrent inhibition by intravenous administration of L-acetylcarnitine in spastic patients. J Neurol Neurosurg Psychiatry 53:321–326
Müller H, Zierski J (1988) Clinical experience with spinal morphine, midazolam and tizanidine in spasticity. In: Müller H, Zierski J, Penn RD (eds) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York, pp 143–150
Müller H, Zierski J, Penn RD (eds) (1988a) Local-spinal therapy of spasticity. Springer, Berlin Heidelberg New York
Müller H, Zierski J, Dralle D, Hoffmann O, Michaelis G (1988b) Intrathecal baclofen in spasticity. In: Müller H, Zierski J, Penn RD (eds) Local-spinal therapy of spasticity. Springer, Berlin Hiedelbergy New York, pp 155–214
Novack GD (1982) Studies on the efficacy and depressant potential of muscle relaxants in mice. Drug Dev Res 2:383–386
Palmeri A, Wiesendanger M (1990) Concomitant depression of locus coeruleus neurons and of flexor reflexes by an a2-adrenergic agonist in rats: a possible mechanism for an a2-mediated muscle relaxation. Neuroscience 34:177–187
Patterson V, Byrnes D (1988) Management of severe spasticity with intrathecal baclofen. J Neurol Neurosurg Psychiatry 51:715
Penn R, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320:1517–1521
Rudick RA, Breton D, Krall RL (1987) The GABA-agonist progabide for spasticity in multiple sclerosis. Arch Neurol 44:1033–1036
Saltuari L, Schmutzhard E, Kofler M, Baumgartner H, Aichner F, Gerstenbrand F (1989) Intrathecal baclofen for intractable spasticity due to severe brain injury. Lancet 2:503–504
Sayers AC, Bürki HR, Eichenberger E (1980) The pharmacology of 5-chloro-4-(2-imidazolin-2- yl-amino)-2, 1, 3-benzothiadiazole (DS 103–282), a novel myotonolytic agent. Arzneimittel Forschung 30:793–803
Snow B, Tsui J, Bhatt M, Hashimoto S, Varelas M, Calne D (1990) Botulinum A toxin is effective for spastic muscle contractions. Mov Disord 5[Suppl 1]:76
Whyte J, Robinson KM (1990) Pharmacologic management. In: Glenn MB, Whyte J (eds) The practical managment of spasticity in children and adults. Lea and Febiger, Philadelphia, pp 201–226
Young RR, Delwaide PJ (1981) Drug therapy of spasticity. N Engl J Med 304:28–33, 96–99
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Emre, M. (1993). New Developments in the Medical Treatment of Spasticity. In: Thilmann, A.F., Burke, D.J., Rymer, W.Z. (eds) Spasticity. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78367-8_36
Download citation
DOI: https://doi.org/10.1007/978-3-642-78367-8_36
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78369-2
Online ISBN: 978-3-642-78367-8
eBook Packages: Springer Book Archive